BYON241108C10000
- 0.01
- 0.000.00%
Beyond Newsroom
Beyond Price Target Cut to $8.00/Share From $14.00 by Barclays
Beyond Is Maintained at Equal-Weight by Barclays
Beyond Analyst Ratings
Barclays Maintains Beyond(BYON.US) With Hold Rating, Cuts Target Price to $8
Biogen's Strategic Shift: Felzartamab's Promise in IgAN and Beyond Fuels Buy Rating
BTIG Maintains Beyond(BYON.US) With Hold Rating
Maxim Group Maintains Beyond(BYON.US) With Buy Rating
Tom Forte Maintains Buy Rating on Beyond Despite Weak Q3 Results, Citing Strategic Vision and Financial Resilience
Beyond Is Maintained at Buy by Maxim Group
Maxim Group Maintains Buy on Beyond, Lowers Price Target to $26
Beyond Price Target Cut to $8.00/Share From $14.00 by Piper Sandler
Wedbush Maintains Beyond(BYON.US) With Buy Rating, Cuts Target Price to $15
A Quick Look at Today's Ratings for Beyond(BYON.US), With a Forecast Between $6 to $14
Piper Sandler Remains a Hold on Beyond Inc (BYON)
Beyond Downgraded to Underperform at BofA After 'Disappointing' Q3 Results
Beyond Downgraded to Underperform From Neutral at BofA
Beyond Is Maintained at Buy by Needham
Beyond Analyst Ratings
Needham Initiates Beyond(BYON.US) With Buy Rating, Announces Target Price $13
Beyond Price Target Announced at $13.00/Share by Needham